Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
alexander wlodawer · DIVISION OF BASIC SCIENCES - NCI · 2023 · $217,282 — Recently, angiotensin-converting enzyme 2 (ACE2) was shown to be a functional receptor for SARS-CoV-2, enabling the virus to enter host target cells. Using structure-based rational design, a chimeric ACE2 peptide was designed by us for use as a ligand for analytical quantitation of SARS-CoV-2. We ai…
di s xia · DIVISION OF BASIC SCIENCES - NCI · 2023 · $149,621 — My group studies membrane proteins using both X-ray crystallography and cryo-EM. For the proposed work, we have obtained/purified recombinant ectodomain of the S protein, the S1 subunit, the RBD domain, the S2 subunit, and the human ACE-2 with the amount sufficient for cryo-EM studies. Currently, we…
David Margulies · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $66,875 — We have successfully engineered and produced a number of SARS-CoV-2 proteins, subunits, and single domain antibodies directed against the RBD. These purified proteins have provided the materials for obtaining high resolution crystal structures of four of these sybodies in complex with the Spike rece…
Raphaela Goldbach-Mansky · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $10,739 — In collaboration with the NIAID COVID consortium we have analyzed longitudinally collected whole blood samples collected for RNA isolation from 84 adult patients hospitalized with severe COVID. We also assessed serum samples from a larger panel of adult patients hospitalized with severe COVID (from …
Florian Krammer · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $612,607 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
Yihong Ye · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2023 · $779,674 — Proteinaceous inclusions termed Lewy bodies (LBs) are a classical hallmark of Parkinson's disease (PD). The primary component of these inclusions is alpha-synuclein (a-syn), a protein with an intrinsic propensity to misfold and aggregate. In PD patients, alpha-syn inclusions first observed in the ol…
Pamela Schwartzberg · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $38,953 — Peripheral blood, tonsil tissues, and adenoid tissues were obtained from 110 children who underwent tonsillectomy at Children's National Hospital from late 2020 to 2021 with the goal of: 1) evaluating the prevalence of prior COVID-19 and epidemiologic risk factors for infection; 2) evaluating the na…
David A. Hafler · YALE UNIVERSITY · 2023 · $483,750 — Elucidating mechanisms of novel mRNA nanoparticle and adenovirus-viral vector vaccine- induced T and B cell activation at the site of vaccination and lymph nodes is of critical importance. Studying patients with autoimmune disease treated with B cell depletion, we will perform a systems analysis to …
HUI-CHEN LU · TRUSTEES OF INDIANA UNIVERSITY · 2023 · $573,941 — SPECIFIC AIMS-Multiscale Imaging Core (MSIC) Addictive substances trigger plasticity at the molecular, cellular and circuit levels that manifest as persistent behavioral changes that may cause substance use disorders. Targeting these changes may lead to novel strategies for preventing or treating su…
TOMAS KIRCHHAUSEN · WASHINGTON UNIVERSITY · 2023 · $752,346 — The long term goal of this study is to understand how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), enters cells and how to block that process through the use of therapeutics. Like other enveloped viruses, SARS-CoV-2 cell entry…
Kristina De Paris · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $249,863 — ABSTRACT The SARS-CoV-2 pandemic has resulted in enormous loss of life and in long-lasting health sequalae in a subset of convalescent patients. Little is known about the impact of SARS-CoV-2 infection on people with primary immune deficiency diseases (PIDD). There is also a lack of guidelines regar…
Jane R Taylor · YALE UNIVERSITY · 2023 · $330,750 — Drug-associated conditioned stimuli (CS), or cues, contribute to both the progression and persistence of addiction. We hypothesize, as have others, that blocking reconsolidation of cocaine-cue memories could prevent cue-induced relapse. Reconsolidation is a process whereby reactivation of a memory r…
YONG-HUI ZHENG · UNIVERSITY OF ILLINOIS AT CHICAGO · 2023 · $399,750 — HIV-1 envelope (Env) glycoprotein (gp) 160 belongs to class I fusion proteins that are also expressed by other highly pathogenic human viruses including influenza A viruses (IAV), Ebola viruses (EBOV), and coronaviruses (CoV) such as SARS-CoV (SARS1), MERS, and SARS-CoV-2 (SARS2). They build spikes …
JOHN P MOORE · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $3,689,011 — Overall Abstract This HIVRAD Program Project renewal application is made in response to PAR-18-319. It contains two Research Projects, one Scientific Core and an Administrative Core, under the direction of Principal Investigator, John P. Moore, PhD (Weill Cornell Medical College; WCMC) and co-Princi…
Syed Saif Hasan · UNIVERSITY OF MARYLAND BALTIMORE · 2023 · $413,345 — PROJECT SUMMARY The secretory pathway is responsible for the biogenesis of soluble and membrane proteins involved in communication, energy transduction, nutrient uptake, and defense. These proteins are synthesized in the endoplasmic reticulum (ER) and then trafficked to Golgi and other organelles su…
Anne Moscona · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2023 · $718,692 — No vaccines or treatments for SARS-CoV-2 are yet available. A simple prophylactic antiviral strategy would protect naïve individuals from infection now. In the future, when vaccines should be available, a prophylactic antiviral will be essential for individuals who do not mount a suitable immune res…
Andrew Ouellette · JACKSON LABORATORY · 2023 · $32,797 — PROJECT SUMMARY To date, there is a significant knowledge gap surrounding the genetic and neuronal mechanisms that regulate cognitive resilience to Alzheimer’s Disease (AD). Without a better understanding of these mechanisms, developing therapeutics to enhance cognitive longevity in the face of AD w…
Guowei Wei · MICHIGAN STATE UNIVERSITY · 2023 · $541,935 — Project Summary Due to massive vaccination, coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been partially under control. However, emerging contagious variants such as Delta are still fueling new waves of infections around t…
Shiqing Xu · TEXAS A&M UNIVERSITY · 2023 · $183,651 — PROJECT SUMMARY/ABSTRACT The current COVID-19 pandemic caused by SARS-CoV-2 has paralyzed much of the world. Encouragingly, a few COVID-19 vaccines have been developed and approved for human immunization. However, existing COVID-19 vaccines target the highly mutable membrane Spike protein of SARS-C…
Kelly Keisen Lee · UNIVERSITY OF WASHINGTON · 2023 · $589,522 — Protein-mediated membrane fusion is essential for a multitude of fundamental biological processes. Despite intensive study, at present we have a limited mechanistic understanding of how fusion protein machinery manipulates lipid membranes in order to induce their fusion. This lack of knowledge is pa…